<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477775</url>
  </required_header>
  <id_info>
    <org_study_id>RFBU 13-I-PRU</org_study_id>
    <nct_id>NCT01477775</nct_id>
  </id_info>
  <brief_title>Customized Choice of Oral P2Y12 Receptor Blocker</brief_title>
  <acronym>PRU-MATRIX</acronym>
  <official_title>Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Society of Invasive Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eustrategy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Italian Society of Invasive Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A subset of patients recruited in the main MATRIX study will be randomized after intervention
      but before discharge to standard of care (the treating physician will decide which oral P2Y12
      inhibitor will be added on top of aspirin) versus a customized approach based on an algorithm
      which integrates phenotypic information, including but not limited to residual on-treatment
      platelet reactivity assessed via VerifyNow P2Y12 Assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 20-30% of clopidogrel treated patients do not adequately respond to the drug and are at
      higher risk for ischemic events including death, myocardial infarction, stroke and stent
      thrombosis.

      Residual high on-treatment platelet reactivity while the patient is on clopidogrel depends on
      a complex interplay of phenotypic (spontaneous platelet reactivity, inflammatory status,
      acuity of the clinical presentation, age, renal function) and genetic variables.

      Two main Loss of function alleles have been identified: 1) CYP450 2C19*2 is present in around
      25% of the Caucasian population and result in a lower amount of clopidogrel active
      metabolite. Carriers of 2C19*2 are at higher risk for death or MI and 2.7 fold increase in
      the risk of stent thrombosis if treated with conventional clopidogrel; 2) ABCB-1 C carriers
      have reduced clopidogrel absorption and they have similarly been shown to be at higher risk
      for ischemic adverse events if treated with clopidogrel. Many investigators have recently
      shown however, that the positive predictive value of genetic testing alone at the time of PCI
      is limited and the knowledge of genetic status alone with respect to the two previously
      described loss of function alleles is only poorly able to identify to long-term clopidogrel
      poor responders. An Algorithm has therefore been developed, combining phenotype information
      which has been shown to risk stratify both ischemic and bleeding events up to one year
      follow-up in PCI patients.

      This algorithm has been developed from a single center retrospective registry. To
      prospectively validate it in the context of a prospective multicenter study, the first 320
      patients recruited in the present study will undergo phenotype at discharge and at 30 days
      and genotype assessment at the time of randomization, irrespective of the group which they
      have been assigned to (i.e. standard of care or gene and phenotype). The hypothesis behind
      this mechanistic sub-study is that the use of this combined phenotype-genotype algorithm will
      increase the proportion of patients at 30 days who will be in the therapeutic range according
      to PRU values from 50% in the standard of care versus 70% in the gene and phenotype group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular death, myocardial infarction, stroke or BARC defined bleeding type 2, 3 or 5</measure>
    <time_frame>1 year</time_frame>
    <description>The time to first occurrence of any of the variables listed above will be reported as primary study outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients in the therapeutic range for residual P2Y12 pathway activity according to PRU values.</measure>
    <time_frame>30 days</time_frame>
    <description>We expect that the prospective use of the previously generated combined phenotype and genotype algorithm will result in an higher proportion of patients being in the therapeutic range with respect to the P2Y12 residual activity (70%) as compared to patients in who the P2Y12 inhibitor is left to the discretion of the treating physician. The first 320 patients recruited in the present study will participate into this mechanistic sub-study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall death</measure>
    <time_frame>1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding type 2</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding type 3</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding type 5</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding classified according to the Bleedscore</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>Stent thrombosis will be reported according to the ARC classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Angioplasty</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Customized choice of the oral P2Y12 receptor blocker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral P2Y12 receptor blocker</intervention_name>
    <description>Free choice among clopidogrel, prasugrel or ticagrelor</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Customized choice for the oral P2Y12 receptor blocker</intervention_name>
    <description>one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.</description>
    <arm_group_label>Customized choice of the oral P2Y12 receptor blocker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients recruited in the main MATRIX study who underwent coronary angioplasty with
             stent placement.

        Exclusion Criteria:

          -  unwillingness to sign this sub study specific informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Valgimigli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Ferrara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Valgimigli, MD, PhD</last_name>
    <phone>3356478877</phone>
    <phone_ext>+39</phone_ext>
    <email>vlgmrc@unife.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Salomone, MD</last_name>
    <phone>3357378767</phone>
    <phone_ext>+39</phone_ext>
    <email>m.salomone@dimensione-ricerca.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Fatebenefratelli e Oftalmico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Cortese, MD</last_name>
      <phone>+393347298103</phone>
      <email>bcortese@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bernardo Cortese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda USL Sirai</name>
      <address>
        <city>Carbonia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Ierna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Salvatore Ierna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Valgimigli, MD, PhD</last_name>
      <phone>3356478877</phone>
      <phone_ext>+39</phone_ext>
      <email>vlgmrc@unife.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Campo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Lodi</name>
      <address>
        <city>Lodi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale dei Colli, Cardiologia SUN</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Calabrò, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Calabrò, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Santarelli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Santarelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Garbo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Garbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. Ospedale Civile di Vimercate</name>
      <address>
        <city>Vimercate</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Garducci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Garducci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico San Marco</name>
      <address>
        <city>Zingonia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicoletta De Cesare, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicoletta De Casare, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011 Jun 21;57(25):2474-83. doi: 10.1016/j.jacc.2010.12.047.</citation>
    <PMID>21679849</PMID>
  </reference>
  <reference>
    <citation>Campo G, Ferraresi P, Marchesini J, Bernardi F, Valgimigli M. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Thromb Haemost. 2011 Oct;9(10):2106-8. doi: 10.1111/j.1538-7836.2011.04457.x.</citation>
    <PMID>21819538</PMID>
  </reference>
  <reference>
    <citation>Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets. 2011;22(6):399-407. doi: 10.3109/09537104.2011.579648. Epub 2011 May 31. Review.</citation>
    <PMID>21627411</PMID>
  </reference>
  <reference>
    <citation>Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15.</citation>
    <PMID>19528337</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>November 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>September 1, 2014</last_update_submitted>
  <last_update_submitted_qc>September 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>coronary stent</keyword>
  <keyword>Oral P2Y12 receptor blocker</keyword>
  <keyword>Platelet reactivity units (PRU)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

